Aug 13, 2020
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis
Jun 15, 2020
Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper
Jun 08, 2020
Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions
Jun 03, 2020
Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline
May 22, 2020
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
May 21, 2020
Hoth Announces Proposed Public Offering of Common Stock
May 04, 2020
AIkido Pharma Inc. Provides Update on Anticipated Distribution Date for Hoth Dividend Distribution
Apr 30, 2020
Notice of Record Date of Hoth Distribution
Apr 24, 2020
Hoth Therapeutics, Inc., Voltron Therapeutics, Inc., & HaloVax Announce Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine
Apr 23, 2020
REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
Apr 22, 2020
Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
Apr 21, 2020
Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study
Apr 09, 2020
Hoth Therapeutics Commences Next Phase of VNLG-152 Study
Apr 02, 2020
Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)
Mar 30, 2020
Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases
Mar 27, 2020
AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution
Mar 23, 2020
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Mar 23, 2020
Hoth Therapeutics Announces Agreement to Joint Development for a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19)
Mar 23, 2020
Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)
Mar 19, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss